VK2735 Reconstitution Calculator
Enter the amount you want to measure. The vial buttons will highlight which vial strengths create cleaner syringe-unit measurements.
What amount do you need?
Type the target amount, then choose mg or mcg. Example: 2mg or 500mcg.
Syringe size:
Possible vial strengths:
Best Match
Good Match
Usable
Harder to Measure
Example VK2735 Titration Schedule
| Parameter | Details |
|---|---|
| Dosage | 7.5 mg, 12.5 mg, or 17.5 mg (Phase 3 studies) |
| Route | Subcutaneous (SC) injection |
| Frequency | Once weekly |
| Cycle Length | 78 weeks (Phase 3), 13 weeks (Phase 2) |
| Half‑life | ~170–250 hours (~7–10 days) |
| Reconstitution | Supplied as a solution; no reconstitution required |
Possible vial strengths:
What Is It?
VK2735
Dual GLP-1 / GIP agonist under investigation.
Bacteriostatic Water
Sterile water containing a bacteriostatic preservative, commonly used when preparing multi-use research vials.
How To Mix VK2735
1
CleanUse alcohol swabs to clean the tops of both vials.
2
Draw BAC WaterDraw the selected amount of bacteriostatic water.
3
Inject SlowlyAdd the liquid slowly down the side of the vial.
4
Swirl GentlyDo not shake. Swirl gently until dissolved.
5
Store ProperlyStore as directed and protect from heat and light.
Best Practices & Common Mistakes
Best Practices
- Use sterile technique.
- Protect from light and heat.
- Store refrigerated when appropriate.
- Use clean syringe-unit math before measuring.
Common Mistakes
- Confusing milligrams with milliliters.
- Choosing an option with awkward decimal units.
- Using too little liquid for very small measurements.
- Shaking the vial aggressively.
VK2735 Storage & Handling
Lyophilized Powder: −20°C (−4°F) for long-term storage (up to 24 months). Refrigeration 2–8°C (36–46°F) for short-term use (up to ~3 months). Original sealed vial in the freezer is safest.
Reconstituted Solution: 2–8°C (36–46°F), use within ~7–14 days. Keep sealed, avoid light, and do not repeat freeze-thaw cycles.
Reconstituted Solution: 2–8°C (36–46°F), use within ~7–14 days. Keep sealed, avoid light, and do not repeat freeze-thaw cycles.
Frequently Asked Questions
VK2735 is an investigational dual GLP-1/GIP receptor agonist from Viking Therapeutics. It is being developed for obesity in both subcutaneous and oral formulations, but it is not FDA-approved or commercially available.
VK2735 targets GLP-1 and GIP receptors, the same hormone-receptor pair used by tirzepatide-style dual incretin therapy. The goal is to affect appetite, body weight, glucose-related signaling, and metabolic regulation, but VK2735 is still in clinical development.
Yes, the subcutaneous formulation is in the Phase 3 VANQUISH obesity program. The oral formulation is separate: Viking has reported Phase 2a oral data and has discussed moving oral VK2735 toward Phase 3 development.
A calculator can only show concentration math, not a treatment dose. For example, if a research vial is labeled 15 mg and brought to 4 mL final volume, the concentration is 3.75 mg/mL; a 1.5 mg research amount would equal 0.40 mL, or 40 units on a U-100 syringe.
Both VK2735 and tirzepatide are GLP-1/GIP dual agonist approaches, but tirzepatide is already approved and marketed, while VK2735 is still investigational. VK2735 may become relevant because Viking is developing both injectable and oral versions, but head-to-head approval-level comparisons are not available.
Practical takeaway: If your real goal is weight or metabolic health, the most useful next step is discussing approved treatment options with a clinician rather than relying on an unapproved compound.
Important: This tool is for informational and research-reference purposes only. Not intended for human or veterinary use.